Table 2 Patient and tumor characteristics by CONUT group.

Age

581

280

0.003

≤ 40

211 (24.5%)

160 (27.5%)

51 (18.2%)

> 40

650 (75.5%)

421 (72.5%)

229 (81.8%)

ER

0.456

+

538 (62.5%)

368 (63.3%)

170 (60.7%)

−

323 (37.5%)

213 (36.7%)

110 (39.3%)

PR

0.505

+

396 (46.2%)

264 (45.4%)

134 (47.9%)

−

465 (53.8%)

317 (54.3%)

146 (52.1%)

HER2

0.253

+

198 (23.0%)

127 (21.9%)

71 (25.4%)

−

663 (77.0%)

454 (78.1%)

209 (74.6%)

Ki-67 status

0.246

+

568 (65.2%)

358 (63.8%)

190 (67.9%)

−

293 (34.8%)

203 (36.2%)

90 (32.1%)

pT Stage

0.003

1

287 (33.3%)

209 (37.3%)

78 (26.0%)

2

449 (52.1%)

283 (50.4%)

166 (55.3%)

3

91 (10.6%)

49 (8.7%)

42 (14.0%)

4

34 (3.9%)

20 (3.6%)

14 (4.7%)

pN Stage

P < 0.001

0

370 (43.0%)

278 (47.9%)

92 (32.7%)

1

309 (35.9%)

203 (35.0%)

106 (37.7%)

2

130 (15.1%)

69 (11.9%)

61 (21.7%)

3

52 (6.0%)

30 (5.2%)

22 (7.8%)

Molecular subtype

0.095

Luminal A

223 (25.9%)

162 (27.9%)

61 (21.8%)

Luminal B

407 (47.3%)

262 (45.1%)

145 (51.8%)

HER2-enriched

135 (15.7%)

87 (15.0%)

48 (17.1%)

TNBC

96 (11.1%)

70 (12.0%)

26 (9.3%)

Histological grade

0.227

I-II

585 (67.9%)

387 (66.6%)

198 (70.7%)

III

276 (32.1%)

194 (33.4%)

82 (29.3%)

Surgery type

0.041

Mastectomy

688 (79.9%)

453 (78%)

235 (83.9%)

BCS

173 (20.1%)

128 (22%)

45 (16.1%)

Chemotherapy

0.057

Yes

606 (70.4%)

397 (68.3%)

209 (74.6%)

No

225 (29.6%)

184 (31.7%)

71 (25.4%)

Hormonal therapy

0.233

Yes

655 (76.1%)

435 (74.9%)

220 (78.6%)

No

206 (26.9%)

146 (25.1%)

60 (21.4%)

Radiotherapy

0.320

Yes

393 (45.6%)

121 (43.2%)

272 (46.8%)

No

468 (54.4%)

159 (56.8%)

309 (53.2%)

Target therapy

0.114

Yes

125 (14.5%)

92 (15.8%)

33 (11.8%)

No

736 (85.5%)

489 (84.2%)

247 (88.2%)